Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

Published Date: 02 May 2026

Approval was based on findings from the phase 3 VERITAC-2 trial showing significantly improved PFS for patients with ESR1-mutated disease.

Read Full News

Latest News

Could Burnout Become the Employer’s Responsibility?

A European Parliament committee is backing employer risk assessments to tackle burnout. But should that mean new binding EU rules?

First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC

DESTINY-Lung04 supports trastuzumab deruxtecan as a new frontline option for patients with advanced HER2-mutant disease, though it failed to improve overall survival.

High CLL Remission Seen With First-Line Triplet Regimen

High 2-year survival rates are seen in treatment-naive patients with CLL receiving a noncovalent BTK inhibitor combined with venetoclax and obinutuzumab.

FET-PET Agent Approved for Glioma Imaging

Floretyrosine F18 is the first amino acid PET imaging agent approved for glioma in the United States.

Brain MRI Surveillance Alone May Be Enough in SCLC

For patients with small-cell lung cancer, skipping preventive cranial radiotherapy in favor of MRI monitoring may improve outcomes.

Can Response-Adapted Surgery Improve Outcomes in HNSCC?

Patients who respond to neoadjuvant immunochemotherapy may be able to undergo less extensive surgery, with high rates of disease control and organ preservation.

Todays Updates

Osimertinib's OS Benefit in Resected NSCLC Persists 8 Years

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

Pelvic RT Tied to Longer Survival in Cervical Cancer

In patients with newly diagnosed stage IVB cervical cancer, adding definitive-dose pelvic radiotherapy to chemotherapy was associated with longer survival compared with chemotherapy alone.

New Data Put ADCs on the Map in Relapsed SCLC

Two B7-H3-directed antibody-drug conjugates substantially improve survival over topotecan among patients with relapsed small cell lung cancer — pointing to a potential new treatment class.

Real-World Liso-Cel Results in MCL Consistent With Trials

Two analyses of liso-cel CAR T-cell therapy in relapsed or refractory mantle cell lymphoma show response rates in the real-world setting similar to those seen in clinical trial populations.

Antibiotic Use in Hospice Linked to Higher Mortality Risk

Antibiotic use in patients under hospice care is associated with an increased risk for mortality; for infectious hospice-qualifying conditions, antibiotic use is linked to extended survival.

Todays Updates

Osimertinib's OS Benefit in Resected NSCLC Persists 8 Years

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

Pelvic RT Tied to Longer Survival in Cervical Cancer

In patients with newly diagnosed stage IVB cervical cancer, adding definitive-dose pelvic radiotherapy to chemotherapy was associated with longer survival compared with chemotherapy alone.

New Data Put ADCs on the Map in Relapsed SCLC

Two B7-H3-directed antibody-drug conjugates substantially improve survival over topotecan among patients with relapsed small cell lung cancer — pointing to a potential new treatment class.

Real-World Liso-Cel Results in MCL Consistent With Trials

Two analyses of liso-cel CAR T-cell therapy in relapsed or refractory mantle cell lymphoma show response rates in the real-world setting similar to those seen in clinical trial populations.

Antibiotic Use in Hospice Linked to Higher Mortality Risk

Antibiotic use in patients under hospice care is associated with an increased risk for mortality; for infectious hospice-qualifying conditions, antibiotic use is linked to extended survival.

Latest News

A European Parliament committee is backing employer risk assessments to tackle burnout. But should that mean new binding EU rules?

DESTINY-Lung04 supports trastuzumab deruxtecan as a new frontline option for patients with advanced HER2-mutant disease, though it failed to improve overall survival.

High 2-year survival rates are seen in treatment-naive patients with CLL receiving a noncovalent BTK inhibitor combined with venetoclax and obinutuzumab.

Floretyrosine F18 is the first amino acid PET imaging agent approved for glioma in the United States.

For patients with small-cell lung cancer, skipping preventive cranial radiotherapy in favor of MRI monitoring may improve outcomes.

Patients who respond to neoadjuvant immunochemotherapy may be able to undergo less extensive surgery, with high rates of disease control and organ preservation.

News All Time

Remote CBT for Insomnia Improves Symptoms During Chemo

A new randomized trial strengthens the case for managing cancer-related insomnia with cognitive-behavioral therapy.

Low Awareness of How to Spot Rare Breast Cancer Identified

Researchers survey US adults to assess their knowledge of inflammatory breast cancer.

Long-Acting Interferon Therapy Approved for ET

Ropeginterferon alfa-2b is designed to provide durable disease control.

Thymus Radiation Exposure Tied to Worse Lung Cancer Outcomes

The thymus is not routinely considered during thoracic radiotherapy planning, but new findings suggest that may need to change.

FDA Approves Rusfertide for Polycythemia Vera

Adding rusfertide to standard-of-care treatment cut phlebotomy rates by more than half in the phase 3 VERIFY trial.

Black Canadians Face Multiple Barriers to Blood Donation

Barriers to blood donations from Black people in Canada are rooted in racism and restrictive policies.

Can Accelerated Salvage RT Improve Prostate Cancer Control?

After biochemical recurrence, hypofractionated RT may be no more effective than standard RT for disease control — and may have more late side effects.

Laser Therapy Shows Promise for Brain Tumors

Researchers followed 787 patients with brain tumors treated with laser therapy for up to 5 years.

Ibrutinib Fails in High-Risk Early-Stage CLL

Ibrutinib improves event-free survival in certain genetic subgroups of early-stage chronic lymphocytic leukemia but fails to extend overall survival.

Sequencing Method Flags AML Relapse Risk Around Transplant

High-sensitivity tracking of a high-risk mutation may help identify risk for relapse in patients with acute myeloid leukemia around the time of allogeneic transplant.

Are Microplastics Feeding Cancer Risk?

Microplastics are everywhere, in the environment and the human body. But as public concern about possible health effects grows, evidence of a cancer connection remains thin.

Does Maintenance Therapy Extend Life in mCRC?

Maintenance therapy is linked to longer overall survival after first-line bevacizumab-based combination chemotherapy in patients with metastatic colorectal cancer, a study finds.

Preschoolers With Cancer Have Poor Motor Skills

Preschool children newly diagnosed with cancer exhibit significant motor impairments, reduced mobility, and weak grip strength at diagnosis, study shows.

Breast Cancer Survivors: Who Benefits From Weight-Loss Meds?

The oral drug naltrexone-bupropion helps some breast cancer survivors lose weight.

Fixed-Duration Combo Shows Promise for Relapsed MCL

Researchers examine the efficacy of fixed-duration mosunetuzumab plus polatuzumab vedotin in patients with heavily pretreated relapsed/refractory mantle cell lymphoma.

Ruxolitinib Reduces Acute GVHD in Transplant Patients

A phase 3 trial evaluates a low-dose ruxolitinib-based regimen for graft-vs-host disease prophylaxis among patients undergoing haploidentical hematopoietic stem-cell transplantation.

Recommended News For You

Cognitive Bias Modification App Fosters Alcohol Avoidance

A study on lung cancer provides additional proof of the value of screening.

CDC Alerts on Dramatic Rise in Human Parvovirus B19

Second Malignancy Risk With CAR T-Cell Therapy on Par With Other Treatments

Vaccine shows promise for pancreatic cancer, study finds

Pain’s Toll: Frailty Risk for Childhood Cancer Survivors

Distribution of fat could influence cancer risk, study suggests

Recommended Articles For You

Hematopoietic Aging Load and Disease Susceptibility: Mechanisms, Clinical Implications, and Management 

Evidence-Based Advances in Hematology for Specialists 

Screening for Occult Platelet Dysfunction: Mechanisms, Clinical Implications, and Evidence-Based Approaches 

Cancer Memory: A Persistent Threat to Tumor Recurrence and Metastasis 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Can 80 Gy Radiation Boost Survival in Prostate Cancer?

2.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

3.

FDA Panel Endorses Capivasertib Use in Prostate Cancer

4.

Small-Town Patients Face Big Hurdles as Rural Hospitals Cut Cancer Care

5.

novel technique for early myelodysplastic syndrome relapse detection in blood cancer patients.

1.

Progressive Changes in Tumor Tissue Fluid Transport and Interstitial Pressure: Mechanisms, Clinical Implications, and Therapeutic Advances

2.

Mastering Modern Oncology: Accreditation, Education, and Research Trends for 2025

3.

Colon cancer: Risk factors, warning signs and treatment options 

4.

Targeting Oncology: Expanding Combinatorial Strategies by 2025

5.

Integrated Techniques in Oncology in the Digital Era

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V

2.

From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2

3.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV

4.

How Platelet Disorders Can Affect the Body

5.

The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot